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PXPEDITED REVIEW
ldosterone Synthase Promoter
olymorphism Predicts Outcome in
frican Americans With Heart Failure
esults From the A-HeFT Trial
ennis M. McNamara, MD,* S. William Tam, PHD,† Michael L. Sabolinski, MD,† Page Tobelmann, BS,*
aren Janosko, MSN,* Anne L. Taylor, MD,‡ Jay N. Cohn, MD,‡ Arthur M. Feldman, MD, PHD,§
anuel Worcel, MD†
ittsburgh and Philadelphia, Pennsylvania; Lexington, Massachusetts; and Rochester, Minnesota
OBJECTIVES We sought to evaluate the effect of the aldosterone synthase promoter polymorphism on heart
failure outcomes for subjects in the African American Heart Failure Trial (A-HeFT).
BACKGROUND Genetic heterogeneity modulates clinical outcomes in subjects with heart failure (HF);
however, little data exist in African American populations. A common polymorphism exists
in the promoter region of the aldosterone synthase gene (CYP11B2) at position344 (T/C).
The 344C allele, associated with higher aldosterone synthase activity, has been linked to
hypertension; however, its impact on outcomes in HF is unknown.
METHODS A total of 354 subjects from A-HeFT participated in the GRAHF (Genetic Risk Assessment
of Heart Failure in African Americans) substudy and were genotyped for the aldosterone
synthase polymorphism. Patients were followed prospectively, and event-free survival (free-
dom from death and HF hospitalization) compared by CYP11B2 genotype.
RESULTS Of the cohort, 218 patients were TT, 114 CT, and 22 patients were CC. Baseline etiology,
blood pressure, and functional class were not significantly different among the 3 cohorts. The
C allele was associated with significantly poorer HF hospitalization-free survival with the best
survival among TT subjects, intermediate for heterozygotes, and the poorest for CC
homozygotes (p  0.018), and a higher rate of death (% death TT/TC/CC  1.8/3.5/18.2,
p  0.001). The TT genotype, more prevalent in blacks, was associated with greater impact
of fixed combination of isosorbide dinitrate and hydralazine on the primary composite end
point (p  0.01).
CONCLUSIONS The aldosterone synthase promoter 344C allele linked to higher aldosterone levels is
associated with poorer event-free survival in blacks with HF. The role of aldosterone receptor
antagonists in diminishing this apparent genetic risk remains to be explored. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.030Cardiol 2006;48:1277–82) © 2006 by the American College of Cardiology Foundation
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ectivation of aldosterone may play an important role in the
rogression of heart failure. Stimulation of myocardial
ldosterone receptors increases apoptosis, resulting in fibro-
is and ventricular remodeling (1). Blockade of the aldoste-
one receptor has been shown to improve heart failure
utcomes. In the RALES (Randomized Aldactone Evalu-
tion Study), the addition of the aldosterone receptor
ntagonist spironolactone improved survival in subjects with
evere heart failure (2). Aldosterone antagonists also reduce
eft ventricular remodeling, and the addition of the selective
From the *University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;
NitroMed Inc., Lexington, Massachusetts; ‡University of Minnesota, Rochester,
innesota; and §Thomas Jefferson Medical College, Philadelphia, Pennsylvania.
he GRAHF substudy of the A-HeFT study was supported, in part, by a research
rant from NitroMed Inc. Drs. Tam, Worcel, and Sabolinski are employees of the
itroMed Corporation. Drs. McNamara, Feldman, Taylor, and Cohn have received
esearch support and/or consulting fees from NitroMed. NitroMed produces a fixed
ombination of isosorbide dinitrate and hydralazine which was evaluated in the
RAHF and AHeFT studies.c
Manuscript received February 7, 2006; revised manuscript received June 12, 2006,
ccepted July 10, 2006.ntagonist eplerenone post-myocardial infarction improves
urvival (3).
Significant clinical heterogeneity exists in heart failure
utcomes, and much of this variability is genetically based.
ldosterone synthase (CYP11B2) is a 9-exon gene occur-
ing on chromosome 8q22 (4). A common single nucleotide
olymorphism, C to T transition for position 344, occurs
ithin the promoter region of CYP11B2 (5). The 344C
llele binds the steroidogenic transcription factor 1 (SF-1) 4
imes more than the T allele (6), and has been linked to
ncreased aldosterone production (7,8). The CYP11B2
romoter polymorphism has been linked to hypertension
9–12) and the 344C allele in particular to the risk of
oronary disease (13,14). Despite the central role of aldo-
terone in heart failure progression, the impact of the
344C allele on clinical outcomes is unknown.
The heart failure phenotype differs in African American
nd white cohorts (15). Hypertension is a more frequent
tiology in blacks, while, despite significant risk factors,
oronary disease is less common. Angiotensin-converting
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16); however, racial differences in the impact of aldosterone
ntagonists have not been investigated. In contrast with
ngiotensin-converting enzyme inhibitors, the nitric oxide
NO) donor combination, isosorbide dinitrate and hydral-
zine (I/H), appears to be more efficacious in blacks. In the
-HeFT (African-American Heart Failure Trial), I/H in
xed combination markedly improved survival in a cohort
ith systolic dysfunction (17).
While the impact of genetic heterogeneity on heart
ailure outcomes has been extensively studied in predomi-
antly white cohorts, few studies have investigated the
mpact of genomic variation in blacks. The GRAHF study
Genetic Risk of Heart Failure in African Americans) was a
enetic substudy of the A-HeFT study. This substudy was
nitiated to explore the impact of functional genomic vari-
tion of heart failure mediators in an African-American
ohort. We investigated the impact of the 344 T/C
olymorphism of the aldosterone synthase promoter in the
RAHF cohort.
ETHOD
tudy population. A total of 354 subjects in the A-HeFT
tudy were enrolled in a genetic substudy, the GRAHF
ubstudy. Inclusion criteria for the A-HeFT study (17)
nclude self designation as African Americans, heart failure
ue to systolic dysfunction, and standard background ther-
py for heart failure with neurohormonal blockade, includ-
ng angiotensin-converting enzyme inhibitors or angioten-
in receptor antagonists, and beta-blockers. Subjects were
andomized to either I/H in fixed combination or placebo in
ddition to standard therapy. The white heart failure cohort
rom the GRACE (Genetic Risk Assessment of Cardiac
vents) trial, a single-center investigation based at the heart
ailure clinic at the University of Pittsburgh (18), was
tilized for comparisons of allele frequencies by race.
enotyping. Subjects were enrolled in the GRAHF study
t the A-HeFT study 6-month visit. Deoxyribonucleic acid
as isolated from peripheral blood by leukocyte centrifuga-
Abbreviations and Acronyms
A-HeFT  African-American Heart Failure Trial
CYP11B2  aldosterone synthase gene locus
GRACE  Genetic Risk Assessment of Cardiac
Events trial
GRAHF  Genetic Risk Assessment of Heart Failure
in African Americans substudy
I/H  isosorbide dinitrate and hydralazine
LVDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
MLHFQ  Minnesota Living with Heart Failure
Questionnaire
NO  nitric oxide
QoL  quality of life
SF-1  steroidogenic transcription factor-1ion and cell lysis (PureGene, Gentra Systems, Minneapolis, cinnesota). The aldosterone synthase (CYP11B2) pro-
oter 344 T/C polymorphism was assessed using a
aqMan SNP Genotyping Assay with tagged primers
ABI, Norwalk, Connecticut), and products were read using
he Applied Biosystems 7000 (Applied Biosystems, Foster
ity, California).
utcomes analysis. Subjects were followed to an end point
f death or heart failure hospitalization. Quality-of-life
QoL) assessment was performed by the Minnesota Living
ith Heart Failure Questionnaire (MLHFQ) at baseline
nd at the 6-month visit. Left ventricular function was
ssessed by transthoracic echocardiography at baseline and 6
onths in a subset (n  273 at baseline, n  268 at 6
onths) of the GRAHF study subjects. The primary end
oint for the A-HeFT study was a composite weighted
core with 3 components: mortality, heart failure hospital-
zation, and change in QoL at 6 months (19). Hardy-
einberg equilibrium was evaluated by chi-square analysis.
vent-free survival was compared by genotype class by
aplan-Meier log rank analysis. The impact of the 344C
llele on aldosterone levels is predicted to be additive, with
omozygous CC subjects having the highest levels, TT
ubjects the lowest, with heterozygous subjects being inter-
ediate. Therefore, a priori a linear model was utilized that
redicts an intermediate phenotype for heterozygotes. Con-
inuous variables such as left ventricular ejection fraction
LVEF) and composite score were compared by genotype
lass by linear analysis of variance (ANOVA). For the
nteraction of aldosterone genotype and the impact of
herapy, ANOVA was used to compare outcomes (compos-
te score and QoL score) by treatment subset (I/H vs.
lacebo) within genotype subsets. For this pharmacogenetic
nalysis, subjects with the C allele (CC and TC genotypes)
ere pooled and compared with the TT genotype subset
iven the limited number of CC subjects.
ESULTS
he GRAHF study population was 60% men, 25% isch-
mic, and 98% New York Heart Association functional class
II, with a mean age of 57. Over the course of follow-up,
here were 60 (17%) heart failure hospitalizations and 12
eaths (3.4%). In terms of the CYP11B2 344 T/C
romoter polymorphism, 218 subjects (62%) were TT, 114
T (32%), and 22 patients were CC (6%). The observed
istribution was consistent with Hardy-Weinberg equilib-
ium (allele frequency T/C  0.78/0.22, expected genotype
requencies % TT/TC/CC  61%/34%/5%, chi-square
xpected vs. observed, p  0.63). Comparisons of baseline
tiology, medical therapy, blood pressure, and functional
lass were not significantly different among the 3 genotype
ubsets (Table 1). The allele frequencies differed markedly
y race, as the T allele was much more prevalent in the black
ohort in the A-HeFT study when compared with the white
ohort from the GRACE study (p  0.001) (Fig. 1).
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September 19, 2006:1277–82 Aldosterone Synthase Polymorphism in Heart Failurevent-free survival. The event-free survival of overall
ubjects in the GRAHF study at 90, 180, and 360 days was
4%, 91%, and 81%, respectively. The C allele was associ-
ted with significantly poorer hospitalization-free survival
Fig. 2) (p  0.018) with the best survival among TT
ubjects (% event-free survival at 90/180/360 days  94/93/
5), intermediate for heterozygotes (% event-free  93/90/
7), and the poorest for CC homozygotes (% event-free 
6/81/63). Mortality in the overall GRAHF study cohort
as significantly greater in subjects with the C allele (%
eaths TT/TC/CC  1.8%, 3.5%, 18.2%; p  0.001).
ldosterone synthase genotype, outcomes and I/H. In
he GRAHF study subpopulation, treatment with I/H was
ssociated with a trend towards improved composite score
placebo  0.09  1.7, I/H  0.22  1.8, p  0.08).
hen analyzed in genotype subset, I/H markedly improved
he composite score among TT homozygotes (placebo 
0.17  1.7, I/H  0.38  1.4, p  0.01) (Fig. 3A), but
ad no impact among subjects with the 344C allele
placebo  0.01  1.8; I/H  0.07  2.0) (Fig. 3A).
hange in MLHFQ QoL score also suggested marked
mprovement in TT subjects, but not among those with the
allele (change in MLHFQ score at 6 months from
aseline, TT subset: placebo  0.6  22.6; I/H  7.4
able 1. Baseline Characteristics by CYP11B2 344 Genotype*
CC (n  22)
ge (yrs) 56.6  12.2
emale (%) 31.8
YHA functional class, % (III/IV) 95.5/4.5
schemic (%) 22.7
VEF core entry (n  270) 0.31  0.07
ystolic BP 125  20
iastolic BP 79  14
herapy
ACE inhibitor (%) 72.7
Aldosterone receptor antagonist 45.5
Beta-blocker (%) 77.3
No significant differences in characteristics by CYP11B2 genotype.
ACE angiotensin-converting enzyme; BP blood pressure; CC344 CC ge
C  344 TC genotype; TT  344 TT genotype.
igure 1. Genotype frequencies for the aldosterone synthase (CYP11B2)
344 T/C polymorphism in the white heart failure cohort in the GRACE
rial and the African American heart failure cohort from GRAHF
ubstudy. The prevalence of the T allele is significantly higher (p  0.001)
n African Americans.
i
b17.0, p  0.038; CC  TC subset: placebo  7.7 
9.0; I/H7.3 20.4, p NS) (lower scores represents
etter QoL) (Fig. 3B).
ldosterone genotype and left ventricular remodeling.
aseline ejection fraction did not differ at baseline among
roups; however, there was a trend toward lower LVEF at
months for subjects with the 344C allele (LVEF % for
enotype subsets: TT/TC/CC  38/37/33, p  0.10)
Table 2). Aldosterone receptor antagonists did not limit
he impact of the C allele on 6-month LVEF, as in fact the
mpact was more pronounced for subjects on antagonists
344C allele linked to lower LVEF, subjects on aldoste-
one receptor antagonists: TT/TC/CC  39/36/32, p 
.03). In contrast with the impact of aldosterone antago-
ists, treatment with I/H appeared to eliminate the impact
f the C allele on remodeling, as the impact on LVEF was
vident among subjects treated with placebo (LVEF: TT/
C/CC  37/36/32, p  0.05) but not for subjects on I/H
LVEF: TT/TC/CC  38/38/40, p  0.79). Consistent
ith the impact of genotype on LVEF, subjects on placebo
n  114) TT (n  218) All Patients (n  354)
 11.8 57.2  13.5 57.4  12.8
34.2 44.5 40.4
.5/3.5 96.8/3.2 96.6/3.4
26.3 25.2 25.4
 0.08 0.35  0.09 0.35  0.09
 17 127  17 127  17
 11 76  10 77  10
74.6 77.1 76.0
33.3 36.5 36.1
86.8 82.6 83.6
e; LVEF left ventricular ejection fraction; NYHANew York Heart Association;
igure 2. Event-free survival by CYP11B2 344 genotype subsets. Free-
om from heart failure hospitalization was significantly poorer (p  0.018)TC (
57.9
96
0.35
128
78n subjects with the C allele, with the worst outcomes in CC homozygotes,
est outcomes in TT subjects, and intermediate in heterozygotes.
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Aldosterone Synthase Polymorphism in Heart Failure September 19, 2006:1277–82ith the C allele had a greater left ventricular end-diastolic
iameter (LVDD) at 6 months (LVDD [cm] TT/TC/CC
6.0/6.3/6.8, p  0.01) (Table 2).
ISCUSSION
n the GRAHF study, the CYP11B2 promoter 344C
llele linked to higher expression of aldosterone synthase
igure 3. Impact of therapy with isosorbide dinitrate and hydralazine
I/H) on outcomes in heart failure. (A) Effect on composite score in 344
enotype subsets. Treatment associated with marked improvement in the
344TT subset (n  218, p  0.01), but minimal effect in subjects with
he 344 C allele (CC  TC, n  136, p  NS). (B) Effect on change
n quality-of-life scores from baseline to 6 months in 344 genotype
ubsets.
able 2. Left Ventricular Ejection Fraction (LVEF) and Left Ve
enotype and Treatment
n TT
VEF (%) 262 38 
VDD (cm) 268 6.1 
VEF on spironolactone (%) 99 39 
VDD (cm) on spironolactone 101 6.2 
VEF on placebo (%) 136 37 
VDD (cm) on placebo 137 6.0 
VEF on I/H (%) 126 38 
VDD (cm) on I/H 131 6.2 Comparisons of means by linear ANOVA.
I/H  isosorbide dinitrate and hydralazine in fixed combination; other abbreviations asas associated with an increased risk of death and hospi-
alization for African American subjects with heart failure.
nalysis by treatment subset suggests the C allele also
orsens left ventricular remodeling. Of interest, the impact
f the NO donor strategy I/H was greatest in subjects with
he TT genotype, a genotype predominant in African
mericans and previously linked to low-renin hypertension.
he results of this investigation suggest that genetic varia-
ion in aldosterone production plays an important role in left
entricular remodeling and disease progression in African
mericans with heart failure, a population underrepresented
n previous genetics outcomes investigations.
While the 344C allele in vitro has increased binding of
F-1 (6), the impact on transcriptional activity and aldo-
terone levels in vivo remains controversial. In clinical
tudies in essential hypertension, the C allele was associated
ith higher circulating levels of aldosterone in a gene-
rdered fashion with the highest levels in the CC genotype
ubset, intermediate in heterozygotes, and lowest in TT
omozygotes (20). However, the linkage of the 344
enotype with aldosterone levels has been inconsistent as
everal reports actually associate the 344T allele with
igher levels (21,22). An analysis from the Framingham
tudy suggests the variance in aldosterone levels in popula-
ions is primarily due to non-genetic factors (23). The
mpact of the CYP11B2 genotype on aldosterone levels may
e dependent on a subject’s overall level of neurohormonal
ctivation. While these previous studies have been done in
ormal subjects or in those with hypertension, little data
xist on the interaction of the 344 T/C polymorphism
ith aldosterone levels in heart failure cohorts.
As demonstrated in the GRAHF study, the344T allele
s consistently more prevalent in black cohorts (21,24). The
eart failure phenotype differs in African American and
hite cohorts (15), with a much greater prevalence of
ypertensive cardiomyopathy. Low-renin hypertension, in
hich the aldosterone/renin ratio is elevated, is particularly
ore prevalent in African Americans (25,26) and has been
inked to the T allele (21,27). In a hypertension study
omparing the aldosterone antagonist eplerenone to angio-
ensin receptor antagonists, eplerenone was more effective
han angiotensin receptor antagonists in black cohorts
lar Diastolic Diameter (LVDD) at 6 Months by 344
TC CC p Value*
37  9 33  8 NS (0.10)
6.2  1.3 6.5  1.3 NS
36  9 32  6 0.03
6.3  1.5 6.5  0.8 NS
36  10 32  7 0.05
6.3  1.2 6.8  0.9 0.01
38  8 40  6 NS
6.0  1.4 5.6  1.9 NSntricu
9
1.3
10
1.4
10
1.3
9
1.4in Table 1.
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September 19, 2006:1277–82 Aldosterone Synthase Polymorphism in Heart Failure28,29). Whether aldosterone antagonists are more effective
s heart failure therapy in African Americans will require
urther investigation.
Stimulation of the myocardium by aldosterone induces
eft ventricular remodeling, hypertrophy, and fibrosis (1). In
Finnish cohort free of cardiac disease, the 344C allele
as associated with increased left ventricular size and mass
30). In a study of 995 members of 229 families, the
YP11B2 haplotype was linked to left ventricular cavity size
nd wall thickness (31). In the current GRAHF study
ohort, the C allele was associated with a trend towards
ower LVEF at 6 months. This was particularly significant
or the subset on placebo and was not evident for subjects
andomized to I/H. Of note, the impact of the C allele was
lso more pronounced for subjects on aldosterone receptor
ntagonists. Aldosterone receptor antagonists were not
andomized in the GRAHF study, and their use may
epresent a marker for higher-risk subjects rather than a
harmacogenetic interaction. Overall, the current study is
onsistent with previous reports of an increased risk of
emodeling with the 344C allele, and this may be the
echanism of its adverse effect on heart failure outcomes.
Low-renin hypertension is associated with endothelial
ysfunction (32) and has been linked to the 344TT
enotype (33). Aldosterone excess in low-renin states is
ssociated with impaired NO-mediated vasodilation (34).
reatment with aldosterone antagonists enhance endothe-
ial nitric oxide synthase (NOS3) expression (35), which
ay help to restore endothelial function and contribute to
heir therapeutic effects in subjects with heart failure. In
-HeFT I, the therapeutic impact of treatment with I/H
as greater in the African American cohort (36), and this
nding was confirmed by the marked benefits in heart
ailure survival with treatment in the A-HeFT study (17).
n the GRAHF study, the impact of I/H was primarily in
ubjects with the 344TT genotype predominant in Afri-
an Americans. Whether NO donor strategies are more
ffective in low-renin states remains to be determined.
While this study suggests the TT genotype subjects
eceived greater benefit from I/H, this finding was driven by
mprovements in the QoL score and reevaluated in a
rospective trial of pharmacogenetic targeting. Indeed,
hough treatment with I/H did not affect composite score in
ubjects with the C allele, therapy did appear to limit the
dverse impact of the C allele on 6-month LVEF, partic-
larly among CC subjects (LVEF 32% placebo vs. 40% on
/H). However, this impact of treatment on left ventricular
emodeling must be viewed with caution given the small
umber of CC subjects.
The design of the A-HeFT and the GRAHF studies
mposed several limitations on this analysis. Circulating
ediators were not evaluated as part of the GRAHF study,
o the impact of the 344 T/C polymorphism on aldoste-
one level was not investigated. The mortality rate for
ubjects in GRAHF (3.4%) was lower than in the A-HeFT
tudy itself, and therefore the ability to evaluate the impactf genotype on survival as a single end point was limited.
reatment with aldosterone receptor antagonists was not
andomized and was utilized in a minority of subjects (39%
n A-HeFT and 36% in the GRAHF cohort), so the impact
f CYP11B2 genotype on treatment designed to block
ldosterone could not be evaluated. Future studies should
valuate the influence of CYP11B3 genotype on treatment
esponse to both aldosterone receptor antagonists.
The current investigation demonstrates that the 344
/C promoter polymorphism of CYP11B2 influences clin-
cal outcomes in an African American cohort with heart
ailure, and provides evidence for the importance of aldo-
terone in heart failure progression. The heart failure
henotype for African Americans differs from whites, and
he allele frequencies of this functional polymorphism differ
arkedly in black and white cohorts. These results from the
RAHF study suggest that genetic variation in aldosterone
roduction may contribute to these phenotypic differences.
n determining optimal heart failure treatment for an
ndividual, race is likely a surrogate marker for differences in
enetic background. Future investigations will determine
he role of genomic markers for tailoring therapy for
ndividuals with heart failure.
eprint requests and correspondence: Dr. Dennis M. McNamara,
eart Failure/Transplantation Program, University of Pittsburgh
edical Center, 566 Scaife Hall, 200 Lothrop Street, Pittsburgh,
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